Slovenia
AIM ImmunoTech Inc (AIM) Q2 2024 Earnings Call Transcript Highlights: Financial Stability and Clinical Progress
Cash, Cash Equivalents, and Marketable Securities: $10.1 million as of June 30, 2024.Research and Development Expenses (Q2 2024): $1.1 million.Research and Dev